Key result
DOACs are associated with shorter hospital stays and less posterior bleeding than VKAs in epistaxis.
Why the study?
Direct oral anticoagulants (DOACs) are increasingly prescribed over vitamin K antagonists (VKAs) for patients on oral anticoagulants with epistaxis, but comparative outcomes remain unclear.
Meta-Analysis (n=1,390)
Standardized Mean Difference: -0.22 (95% CI -0.42–-0.02)
p-value: p=.03
No takes yet. Share an insight, caveat, or question.
DOACs yield shorter stays and fewer posterior bleeds than VKAs in epistaxis; reinforces guideline preference for DOACs in anticoagulated patients.
Stanković et al. (2021) conducted a meta-analysis in Epistaxis (n=1,390). Direct oral anticoagulants (DOAC) vs. Vitamin K antagonists (VKA) was evaluated on Hospital stay duration (SMD -0.22, 95% CI -0.42 to -0.02, p=.03). Direct oral anticoagulants were associated with shorter hospital stays (SMD -0.22; 95% CI -0.42 to -0.02; p=0.03) and lower posterior bleeding rates compared to VKAs in epistaxis patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: